HRS-4642+AG+Nimotuzumab
CAPT05
Phase 2 small_molecule active
Quick answer
HRS-4642+AG+Nimotuzumab for Borderline Resectable Pancreatic Adenocarcinoma is a Phase 2 program (small_molecule) at Zhejiang University with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Zhejiang University
- Indication
- Borderline Resectable Pancreatic Adenocarcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active